Humacyte carefully manages its capital structure, utilizing targeted debt arrangements, private placements, and registered direct offerings of common stock to fund ongoing operational activities. Its precise debt-to-equity ratios fluctuate dynamically following periodic financial restructurings, warrant conversions, and capital raises designed to extend its cash runway as it scales commercial manufacturing capabilities.